A New Era in Colorectal Cancer Therapy

Backed by $17M in non-dilutive funding, Barricade is advancing a first-in-class oral therapy designed to change how colorectal cancer is treated.

View Investment Opportunity

Why Colorectal Cancer Needs a New Approach

Watch the Video | 3:50

Colorectal cancer is one of the leading causes of cancer-related death worldwide — and recent reporting shows it has become the leading cause of cancer death among younger adults, a troubling shift that underscores how poorly current treatments are keeping pace with the disease. In this video, Barricade’s founder and scientific leadership explain why today’s standard of care falls short for most patients, what’s happening at the biological level in colorectal cancer, and why a fundamentally different investigational approach is needed to change outcomes.

BT-1501 is investigational and not FDA approved. Investing involves risk, including possible loss of investment.

The Problem

Colorectal Cancer Kills Nearly 50% of Patients

A Disease Still Winning

Colorectal cancer remains one of the deadliest cancers worldwide. Despite decades of medical advancement, nearly half of all diagnosed patients will die from the disease—especially once it reaches advanced stages.

Outcomes have not meaningfully improved for many patients, and the disease is now rising fastest among younger adults. Recent reporting from major medical and national outlets has highlighted a troubling trend: more patients are being diagnosed later, when treatment options are limited, therapies are more toxic, and survival drops sharply.

For most patients, existing treatments fail to address the underlying genetic drivers of the disease. Care often relies on non-targeted, burdensome regimens that are difficult to tolerate and frequently ineffective—particularly in advanced colorectal cancer.

This is not an incremental gap.
It represents a fundamental failure in how colorectal cancer is treated today.

Barricade was founded to confront this reality—by targeting the most common genetic drivers of colorectal cancer and developing a more precise, patient-centered therapeutic approach.

The Solution

A Targeted Oral Therapy

A Targeted, Oral Approach to Colorectal Cancer

Barricade is developing BT-1501, a first-in-class oral therapy designed to target the genetic drivers most commonly responsible for colorectal cancer.

Unlike conventional treatments that rely on broad, toxic regimens, BT-1501 is intended to act at the origin of tumor growth—where disease progression begins.

By focusing on well-validated genetic mechanisms and delivering therapy in an oral form, Barricade aims to reduce treatment burden while improving precision, tolerability, and long-term potential outcomes for patients.

BT-1501 has demonstrated tumor-targeting and cell-disruption activity in preclinical studies and is being advanced as a once-daily oral tablet.

Independent Validation from Leading Institutions

Non-dilutive funding, peer-reviewed support, and long-dated IP validate Barricade’s scientific and development foundation.

$17M in Non-Dilutive CPRIT Funding

Barricade has secured $17 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT), one of the largest public funders of cancer research in the United States.

CPRIT funding supports advancement of BT-1501 toward IND submission and first-in-human clinical trials and is awarded through a rigorous scientific and regulatory review process.

Investment from the American Cancer Society

Barricade is backed by the American Cancer Society’s BrightEdge Fund, a mission-driven investor supporting the development of high-impact cancer therapies.

BrightEdge participation provides external scientific validation and reinforces Barricade’s patient-focused development strategy.

Strong Global IP Position

Barricade holds issued composition-of-matter and method-of-use patents protecting BT-1501 and the TASIN platform through 2039, with additional expansion potential.

Freedom-to-operate analyses have been completed with no blocking intellectual property identified.

The Opportunity

A Multibillion-Dollar Oncology Market with Persistent, Unmet Demand

Why This Market Creates Long-Term Investment Opportunity

Current colorectal cancer treatments remain costly, complex, and burdensome, reinforcing demand for innovation.

  • Many leading therapies rely on injectables or combination regimens with limited durability

  • Strong clinical and commercial demand exists for oral therapies that can be used earlier, longer, or alongside existing standards of care

  • Long treatment timelines and recurring use support durable commercial potential

BT-1501 is being developed to address this unmet need within a large, established, and growing global oncology market.

As patients progress through multiple lines of therapy, treatment options become increasingly limited, reinforcing long-term demand for new, differentiated approaches.

The Scale and Urgency of the Colorectal Cancer Market

Colorectal cancer remains one of the largest and deadliest cancer markets worldwide, driven by high incidence, long treatment durations, and limited durable options across multiple disease stages.

  • Over $13B global colorectal cancer market, with continued expansion expected

  • More than 1.9 million new cases diagnosed globally each year

  • Approximately 935,000 deaths annually, underscoring the magnitude of unmet need

  • Growth sustained by disease progression, treatment resistance, and lack of curative options

Despite advances in biologics and immunotherapy, most patients eventually exhaust existing treatments — creating ongoing demand for new, differentiated therapies.

Executive Leadership

  • Neil C. Thapar, PharmD, RPh

    Co-Founder, Board Chairman, Chief Executive Officer & Chief Scientific Officer

  • John Walling, PhD

    Co-Founder, SVP, CMC

  • Mariam E. Morris

    Chief Operating Officer

  • Scott Jordan, MBA

    Chief Financial Officer

Barricade Therapeutics

Barricade Therapeutics is a clinical-stage oncology company focused on developing first-in-class oral therapies for genetically driven cancers with significant unmet need.

Led by experienced scientific, clinical, and financial leadership, Barricade is advancing BT-1501—an oral EBP inhibitor designed to target the underlying drivers of colorectal cancer. The company’s approach prioritizes precision, patient tolerability, and durable therapeutic potential across large, established oncology markets.

With independent validation from leading institutions, long-dated intellectual property, and a clear development pathway, Barricade is positioned to translate rigorous science into meaningful clinical and commercial impact.

Why Invest Now

#1 Leading Cause of Cancer Death in Adults Under 50

Colorectal cancer is now the top cancer killer for adults under 50 in the U.S., with incidence accelerating despite increased screening awareness.

#2 Cause of Cancer Death Overall in the U.S.

Across all age groups, colorectal cancer remains one of the deadliest malignancies nationwide, reflecting a persistent and growing unmet need.

Limited Effective Options in Advanced Disease

Patients with metastatic colorectal cancer face limited therapeutic innovation and low durable response rates under current standards of care.

High Rates of Therapeutic Resistance

Late-stage tumors frequently develop resistance to standard therapies, driving progression, recurrence, and poor long-term outcomes.

Stay Informed on Barricade’s Progress

Receive clinical milestones, funding updates, and development announcements.